Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
61.48
-1.95 (-3.07%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Eton Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 105.6 | 79.95 | 39.01 | 31.64 | 21.25 | 21.83 | |
Revenue Growth | 81.49% | 104.94% | 23.29% | 48.90% | -2.66% | 55879.49% |
Cost of Revenue | 40.75 | 32.12 | 15.6 | 10.58 | 6.93 | 2.83 |
Gross Profit | 64.85 | 47.83 | 23.41 | 21.06 | 14.32 | 19.01 |
Selling, General & Admin | 38.45 | 35.24 | 22.34 | 18.93 | 18.58 | 14.27 |
Research & Development | 5.76 | 7.77 | 3.26 | 3.32 | 4 | 6.23 |
Operating Expenses | 44.21 | 43 | 25.59 | 22.25 | 22.58 | 20.5 |
Operating Income | 20.64 | 4.83 | -2.18 | -1.19 | -8.26 | -1.5 |
Interest Expense | -4.57 | -4.78 | -2.01 | -1.06 | -0.96 | -1.04 |
Interest & Investment Income | 1.01 | 1.07 | 0.79 | 1.56 | 0.19 | 0.04 |
EBT Excluding Unusual Items | 17.08 | 1.12 | -3.39 | -0.69 | -9.02 | -2.5 |
Merger & Restructuring Charges | -4.33 | -5.68 | -0.42 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.18 |
Other Unusual Items | - | - | - | - | - | 0.37 |
Pretax Income | 12.75 | -4.56 | -3.81 | -0.69 | -9.02 | -1.96 |
Income Tax Expense | 0.06 | 0.04 | 0.02 | 0.25 | - | - |
Net Income | 12.69 | -4.6 | -3.82 | -0.94 | -9.02 | -1.96 |
Net Income to Common | 12.69 | -4.6 | -3.82 | -0.94 | -9.02 | -1.96 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 27 | 26 | 26 | 25 | 25 |
Shares Outstanding (Diluted) | 30 | 27 | 26 | 26 | 25 | 25 |
Shares Change | 11.94% | 3.91% | 0.97% | 1.99% | -0.24% | 19.98% |
EPS (Basic) | 0.47 | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 |
EPS (Diluted) | 0.43 | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | 14.73 | 10.19 | 0.94 | 6.82 | 4.78 | -4.73 |
Free Cash Flow Per Share | 0.50 | 0.38 | 0.04 | 0.27 | 0.19 | -0.19 |
Gross Margin | 61.41% | 59.83% | 60.01% | 66.56% | 67.38% | 87.05% |
Operating Margin | 19.54% | 6.04% | -5.59% | -3.77% | -38.87% | -6.85% |
Profit Margin | 12.02% | -5.75% | -9.80% | -2.96% | -42.45% | -8.96% |
Free Cash Flow Margin | 13.95% | 12.75% | 2.42% | 21.54% | 22.51% | -21.66% |
EBITDA | 25.18 | 8.88 | -1.04 | -0.29 | -6.49 | -1.12 |
EBITDA Margin | 23.84% | 11.10% | -2.66% | -0.92% | -30.52% | -5.13% |
D&A For EBITDA | 4.54 | 4.04 | 1.15 | 0.9 | 1.77 | 0.37 |
EBIT | 20.64 | 4.83 | -2.18 | -1.19 | -8.26 | -1.5 |
EBIT Margin | 19.54% | 6.04% | -5.59% | -3.77% | -38.87% | -6.85% |
Revenue as Reported | 105.6 | 79.95 | 39.01 | 31.64 | 21.25 | 21.83 |